Invivo Partners

ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of our products.

Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure.

Integra Therapeutics is a developer of next-generation of gene editing tools to cure diseases.

Telomere Therapeutics creates gene therapy based on telomerase gene expression for the treatment of age-related diseases like idiopathic pulmonary fibrosis, aplastic anemia, or dyskeratosis congenita.

MiiMOSA operates a crowd funding platform dedicated to agriculture and food.

Telomere Therapeutics creates gene therapy based on telomerase gene expression for the treatment of age-related diseases like idiopathic pulmonary fibrosis, aplastic anemia, or dyskeratosis congenita.

OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.

ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of our products.

Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages.

Gyala Therapeutics is focused on developing new CAR-T therapies for treating hematological malignancies. CAR-T (chimeric antigen receptor T cells) is a type of gene therapy in which T lymphocytes -a type of white blood cells that play a key role in immune responses- are extracted from the patient and modified to attack tumour cells. T lymphocytes are obtained through apheresis (a technique that allows separation of blood components) and genetically reprogrammed with a receptor that binds to a tumor factor. When these cells are transduced back to the patient, they are to specifically recognize tumour cells and attack them. Several types of CAR-T cells have demonstrated efficacy in the treatment of leukemias and B cell lymphomas.

Pulmobiotics is a Barcelona, Spain-based pre-clinical life sciences company using synthetic biology to develop new treatments and vaccines for various types of lung diseases.

ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of our products.